PE20010480A1 - PRODUCTOS DE DROGAS ß-CARBOLINE - Google Patents
PRODUCTOS DE DROGAS ß-CARBOLINEInfo
- Publication number
- PE20010480A1 PE20010480A1 PE2000000773A PE0007732000A PE20010480A1 PE 20010480 A1 PE20010480 A1 PE 20010480A1 PE 2000000773 A PE2000000773 A PE 2000000773A PE 0007732000 A PE0007732000 A PE 0007732000A PE 20010480 A1 PE20010480 A1 PE 20010480A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- particles
- refers
- carboline
- diluents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMA PARTICULADA DE DROGA LIBRE DE UN COMPUESTO ß-CARBOLINE DE FORMULA I QUE COMPRENDE PARTICULAS DEL COMPUESTO DONDE AL MENOS 90% DE LAS PARTICULAS TIENEN UN TAMANO DE PARTICULA DE MENOS DE 40 MICRONES. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE UN COMPUESTO I; PORTADORES, DILUYENTES, EXCIPIENTES QUE MUESTRAN UNA CMAX DE 180µg/L A 280 µg/L USANDO UNA DOSIS DE 10 mg DE COMPUESTO. TAMBIEN SE REFIERE A UN METODO PARA LA ELABORACION DE LA FORMA PARTICULADA DE LA DROGA LIBRE QUE COMPRENDE PROPORCIONAR UNA FORMA LIBRE DEL COMPUESTO; PULVERIZAR LA FORMA LIBRE SOLIDA DEL COMPUESTO PARA PROPORCIONAR PARTICULAS DEL COMPUESTO DONDE AL MENOS EL 90% DE LAS PARTICULAS TIENE UN TAMANO DE PARTICULA DE MENOS DE 40 MICRONES; MEZCLAR LAS PARTICULAS CON DILUYENTES, EXCIPIENTES. EL COMPUESTO I ES UN INHIBIDOR DE 3`,5'-GUANOSINMONOFOSFATO FOSFODIESTERASA TIPO 5 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DISFUNCION SEXUAL COMO ERECCION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14704899P | 1999-08-03 | 1999-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010480A1 true PE20010480A1 (es) | 2001-05-26 |
Family
ID=22520112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000773A PE20010480A1 (es) | 1999-08-03 | 2000-08-03 | PRODUCTOS DE DROGAS ß-CARBOLINE |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1200092B1 (es) |
| JP (1) | JP4456788B2 (es) |
| KR (1) | KR20020063842A (es) |
| CN (2) | CN101134019A (es) |
| AR (1) | AR033953A1 (es) |
| AT (1) | ATE264680T1 (es) |
| AU (1) | AU773666B2 (es) |
| BR (1) | BR0012901A (es) |
| CA (1) | CA2380087C (es) |
| CO (1) | CO5200849A1 (es) |
| CZ (1) | CZ300151B6 (es) |
| DE (1) | DE60010089T2 (es) |
| DK (1) | DK1200092T3 (es) |
| DZ (1) | DZ3180A1 (es) |
| EA (1) | EA004302B9 (es) |
| ES (1) | ES2220506T3 (es) |
| HK (1) | HK1044278B (es) |
| HR (1) | HRP20020091B1 (es) |
| HU (1) | HU229443B1 (es) |
| IL (1) | IL147642A0 (es) |
| MX (1) | MXPA02001197A (es) |
| MY (1) | MY125428A (es) |
| NO (1) | NO321602B1 (es) |
| NZ (1) | NZ516613A (es) |
| PE (1) | PE20010480A1 (es) |
| PL (1) | PL199469B1 (es) |
| PT (1) | PT1200092E (es) |
| SK (1) | SK286365B6 (es) |
| SV (1) | SV2002000137A (es) |
| TW (1) | TWI235658B (es) |
| UA (1) | UA71629C2 (es) |
| WO (1) | WO2001008688A2 (es) |
| ZA (1) | ZA200200825B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ3179A1 (fr) * | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Compositions pharmaceutiques à base de beta-carboline. |
| EP2216329A1 (en) * | 2004-10-28 | 2010-08-11 | Dr. Reddy's Laboratories Ltd. | Processes for the preparation of tadalafi |
| PT1808164E (pt) | 2006-01-05 | 2009-03-17 | Teva Pharma | Método de granulação húmida para a preparação de composições farmacêuticas de aripiprazole |
| DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
| MD4009C2 (ro) * | 2008-07-15 | 2010-08-31 | Институт Химии Академии Наук Молдовы | Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos |
| DE102009033396A1 (de) | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
| DE102009035211A1 (de) | 2009-07-29 | 2011-02-17 | Ratiopharm Gmbh | Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung |
| WO2012085927A2 (en) * | 2010-12-02 | 2012-06-28 | Mylan Laboratories, Limited | Tadalafil compositions |
| WO2012095151A1 (en) | 2010-12-23 | 2012-07-19 | Zaklady Farmaceutyczne Polpharma Sa | Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof |
| RU2013141446A (ru) | 2011-02-10 | 2015-03-20 | Синтон Бв | Фармацевтическая композиция, содержащая тадалафил и циклодекстрин |
| WO2012107090A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Granulated composition comprising tadalafil and a disintegrant |
| WO2012107092A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| JP5930686B2 (ja) * | 2011-12-07 | 2016-06-08 | 株式会社トクヤマ | 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法 |
| KR102268696B1 (ko) | 2012-03-15 | 2021-06-23 | 메르크 파텐트 게엠베하 | 전자 소자 |
| WO2014003677A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising solid dispersion particles containing tadalafil |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| CN105310984A (zh) * | 2014-06-10 | 2016-02-10 | 合肥贝霓医药科技有限公司 | 一种pde5抑制剂的超微粉体及其制备方法 |
| JP6445559B2 (ja) * | 2014-06-24 | 2018-12-26 | ウーシン ラボタチ カンパニー, リミテッドWooshin Labottach Co., Ltd. | タダラフィルを含む口腔内崩壊フィルム製剤およびその製造方法 |
| SI3466951T1 (sl) | 2014-07-23 | 2022-05-31 | Krka, D.D., Novo Mesto | Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila |
| JP2016106139A (ja) * | 2016-03-07 | 2016-06-16 | 株式会社トクヤマ | 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法 |
| BR112020012986A2 (pt) | 2017-12-26 | 2020-12-01 | Ftf Pharma Private Limited | formulações orais líquidas para inibidores de pde v |
| EP3510997B1 (en) | 2018-01-10 | 2020-08-05 | Gap S.A. | Soft gelatin capsules comprising a suspension of tadalafil |
| CN110638770B (zh) * | 2019-10-25 | 2022-04-05 | 株洲千金药业股份有限公司 | 他达拉非片剂的制备方法及以该方法制得的片剂 |
| EP4531815A1 (en) * | 2022-05-27 | 2025-04-09 | Rontis Hellas S.A. | Improved pharmaceutical composition containing tadalafil and nanomilling process for the preparation thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618845A (en) * | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| GB9511220D0 (en) * | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
-
2000
- 2000-01-08 UA UA2002010773A patent/UA71629C2/uk unknown
- 2000-08-01 CZ CZ20020387A patent/CZ300151B6/cs not_active IP Right Cessation
- 2000-08-01 PL PL353268A patent/PL199469B1/pl unknown
- 2000-08-01 EA EA200200119A patent/EA004302B9/ru not_active IP Right Cessation
- 2000-08-01 DZ DZ003180A patent/DZ3180A1/xx active
- 2000-08-01 AT AT00952371T patent/ATE264680T1/de active
- 2000-08-01 WO PCT/US2000/020981 patent/WO2001008688A2/en active Search and Examination
- 2000-08-01 HU HU0202781A patent/HU229443B1/hu unknown
- 2000-08-01 BR BR0012901-1A patent/BR0012901A/pt not_active Application Discontinuation
- 2000-08-01 KR KR1020027001407A patent/KR20020063842A/ko active Search and Examination
- 2000-08-01 SK SK172-2002A patent/SK286365B6/sk not_active IP Right Cessation
- 2000-08-01 CN CNA2007101408018A patent/CN101134019A/zh active Pending
- 2000-08-01 AU AU65084/00A patent/AU773666B2/en not_active Expired
- 2000-08-01 CN CN00813777A patent/CN1377270A/zh active Pending
- 2000-08-01 IL IL14764200A patent/IL147642A0/xx active IP Right Grant
- 2000-08-01 EP EP00952371A patent/EP1200092B1/en not_active Expired - Lifetime
- 2000-08-01 ES ES00952371T patent/ES2220506T3/es not_active Expired - Lifetime
- 2000-08-01 JP JP2001513418A patent/JP4456788B2/ja not_active Expired - Lifetime
- 2000-08-01 CA CA002380087A patent/CA2380087C/en not_active Expired - Lifetime
- 2000-08-01 DK DK00952371T patent/DK1200092T3/da active
- 2000-08-01 DE DE60010089T patent/DE60010089T2/de not_active Expired - Lifetime
- 2000-08-01 MX MXPA02001197A patent/MXPA02001197A/es active IP Right Grant
- 2000-08-01 NZ NZ516613A patent/NZ516613A/en not_active IP Right Cessation
- 2000-08-01 PT PT00952371T patent/PT1200092E/pt unknown
- 2000-08-02 CO CO00058156A patent/CO5200849A1/es not_active Application Discontinuation
- 2000-08-02 MY MYPI20003524 patent/MY125428A/en unknown
- 2000-08-03 PE PE2000000773A patent/PE20010480A1/es not_active IP Right Cessation
- 2000-08-03 TW TW089115586A patent/TWI235658B/zh not_active IP Right Cessation
- 2000-08-03 AR ARP000104015A patent/AR033953A1/es not_active Application Discontinuation
- 2000-08-07 SV SV2000000137A patent/SV2002000137A/es unknown
-
2002
- 2002-01-29 HR HR20020091A patent/HRP20020091B1/xx not_active IP Right Cessation
- 2002-01-30 ZA ZA200200825A patent/ZA200200825B/en unknown
- 2002-02-01 NO NO20020531A patent/NO321602B1/no unknown
- 2002-06-19 HK HK02104540.5A patent/HK1044278B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010480A1 (es) | PRODUCTOS DE DROGAS ß-CARBOLINE | |
| EA200000718A1 (ru) | Композиции целекоксиба | |
| RS53767B1 (en) | PROCEDURE FOR TREATMENT OF JOINT INJURY | |
| AR067495A1 (es) | Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco | |
| NZ514574A (en) | Novel method of treatment | |
| EA200400007A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ | |
| CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
| CO5680109A1 (es) | Compuestos para el tratamiento de la disfuncion sexual femenina | |
| UY27466A1 (es) | Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides | |
| HK1057899A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| BR0009200A (pt) | Compostos e composições para o tratamento dedoenças associada com disfunção imune | |
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| WO2005069933A3 (en) | Methods of treating an inflammatory-related disease | |
| BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
| HK1087702A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| CO5160329A1 (es) | Metodo para proveer absorcion incrementada de una amina far- maceuticamente aceptable en la sangre de un humano y composi cion que comprende una amina farmaceuticamente un farmaco antiinflamatorio no esteroidal | |
| DE69940557D1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| AR021912A1 (es) | Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones | |
| CO5280073A1 (es) | Composiciones | |
| CO5590913A2 (es) | Terapia de combinacion antivirica | |
| AR029373A1 (es) | Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas | |
| CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
| KR970705553A (ko) | 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents) | |
| DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| MK | Expiration of term |